|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096979 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-10 16:11:15 |
|
注册时间: Date of Registration: |
2025-02-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
利用胸腔内窥镜手术系统完成5G远程机器人辅助手术的安全性与有效性的临床研究 |
|
Public title: |
A clinical trial on the safety and effectiveness of 5G remote robot-assisted surgery was completed using the thoracic endoscopic surgery system |
|
注册题目简写: |
5G远程机器人辅助胸腔镜手术初步研究 |
|
English Acronym: |
Preliminary study on 5G remote robot assisted thoracoscopic surgery |
|
研究课题的正式科学名称: |
利用胸腔内窥镜手术系统完成5G远程机器人辅助手术的安全性与有效性的临床研究 |
|
Scientific title: |
A clinical trial on the safety and effectiveness of 5G remote robot-assisted surgery was completed using the thoracic endoscopic surgery system |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
左庄 |
研究负责人: |
苟云久 |
|
Applicant: |
ZhuangZuo |
Study leader: |
YunjiuGou |
|
申请注册联系人电话: Applicant telephone: |
+86 158 9801 8623 |
研究负责人电话:
Study leader's |
+86 139 1912 7670 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2419503222@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
gouyunjiu@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
甘肃省兰州市城关区东岗西路204号 |
研究负责人通讯地址: |
甘肃省兰州市城关区东岗西路204号 |
|
Applicant address: |
204 Donggang West Road, Chengguan District, Lanzhou City, Gansu Province |
Study leader's address: |
204 Donggang West Road, Chengguan District, Lanzhou City, Gansu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
甘肃中医药大学 |
||
|
Applicant's institution: |
Gansu University of Chinese Medicine |
||
|
研究负责人所在单位: |
甘肃省人民医院 |
||
|
Affiliation of the Leader: |
Gansu Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-770 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
甘肃省人民医院伦理委员会 |
||
|
Name of the ethic committee: |
ethics Committee of Gansu Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-27 00:00:00 | ||
|
伦理委员会联系人: |
齐晓敏 |
||
|
Contact Name of the ethic committee: |
Xiaomin Qi |
||
|
伦理委员会联系地址: |
甘肃省兰州市城关区东岗西路204号东区门诊伦理委员会办公室 |
||
|
Contact Address of the ethic committee: |
Office of East Outpatient Ethics Committee, 204 Donggang West Road, Chengguan District, Lanzhou City, Gansu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 931 828 1223 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
甘肃省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Gansu Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
甘肃省兰州市城关区东岗西路204号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
204 Donggang West Road, Chengguan District, Lanzhou City, Gansu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
甘肃省人民医院胸外科 |
||||||||||||||||||||||
|
Source(s) of funding: |
Department of Thoracic Surgery, Gansu Provincial People's Hospital |
||||||||||||||||||||||
|
研究疾病: |
肺癌、肺良性肿物、纵隔肿物等。 |
||||||||||||||||||||||
|
Target disease: |
Lung cancer, lung benign mass, mediastinal mass, etc. |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
探索5G远程机器人治疗胸外科疾病的安全性与有效性 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the safety and effectiveness of 5G remote robot in treating thoracic surgery diseases |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入标准 (1) 18 周岁≤年龄≤80 周岁; (2) 需接受胸腔内窥镜手术治疗,并有相应手术治疗指征,包括但不限于以下术式:肺段/肺叶切除术、纵膈肿瘤切除术; (3) 生理状况可接受胸腔镜手术者; (4) 愿意配合并完成研究随访及相关检查者; (5) 受试者或其代理人自愿参加本试验并书面签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria (1) 18 years old <= age <=80 years old; (2) Endoscopic thoracic surgery with corresponding surgical indications, including but not limited to the following operations: segmental/lobectomy, mediastinal tumor resection; (3) Patients whose physiological condition is acceptable for thoracoscopic surgery; (4) Willing to cooperate with and complete the study follow-up and related tests; (5) The subjects or their agents voluntarily participate in the experiment and sign the informed consent in person. |
||||||||||||||||||||||
|
排除标准: |
排除标准 (1) 妊娠或哺乳期女性; (2) 恶性肿瘤临床分期为 IV 期者; (3) 需行急诊手术者; (4) 存在活动性出血、凝血功能异常(凝血酶原时间(PT)或国际标准化比值(INR)高于正常值上限 1.5 倍)或血小板计数<80×10^9/L 者; (5) 有严重心血管或循环系统疾病不能耐受手术者; (6) 近 1 个月内参与过其他临床试验者; (7) 无法理解试验要求,或不能完成研究随访计划者; (8) 研究者认为有其他不适合入组的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria (1) Pregnant or lactating women; (2) The clinical stage of malignant tumor is IV; (3) Patients in need of emergency surgery; (4) Active bleeding, abnormal coagulation function (prothrombin time (PT) or International normalized ratio (INR) is 1.5 times higher than the upper limit of normal) or platelet count < 80×10^9/L; (5) Patients with serious cardiovascular or circulatory diseases who cannot tolerate surgery; (6) Participants in other clinical trials within the last 1 month; (7) Unable to understand the trial requirements, or unable to complete the study follow-up plan; (8) The researcher believes that there are other circumstances that are not suitable for inclusion. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-10 00:00:00至 To 2025-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-10 00:00:00 至 To 2025-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:病例记录表 数据管理:电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: Case record form Data Management: Electronic Collection and Management System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |